Blog - Page 5 of 11 - Frier Levitt Government Affairs

Health Policy Check Up News
Our blog provides timely insight on the latest industry trends. We discuss manufacturing, acute and post-acute care issues.
Stay current with our latest insights.
Δ

April 8, 2019

FDA Seeking Comments on New Guidance Regarding Rare Diseases

March 29, 2019

What You Need to Know about Biosimilars with Brian Lehman, Director, Medical Account Management and Strategic Alliances for Sandoz Inc.

March 28, 2019

Biosimilar Naming: Where We’ve Been and Where We Are

March 27, 2019

Will PBM Transparency Help Biosimilar Utilization?

March 22, 2019

2019 Specialty Drug Pipeline & Policy Outlook: A Glimpse into Potential Blockbuster Drugs and the Policies that Govern Them Webinar Recording

March 14, 2019

Don’t Ignore the Steady Drumbeat of Drug Importation

March 12, 2019

ONC and CMS Introduce Proposed Rules on Target Data Blocking

February 8, 2019

Sweeping Proposed Rule on Rebate Safe Harbor has Potential to Impact all Drug Supply Chain Stakeholders

February 6, 2019

New FDA Proposed Rule Looking to Define the Term “Biological Product” Seeks Comments

February 4, 2019

Comments Wanted: New ICER Report to Assess if Clinical Evidence Exists for Significant Increase in Prescription Drug Prices